Global virus outbreaks: Interferons as 1st responders

Seminars in Immunology

Volumn 43, Issue , 2019, Pages

  Wang, Ben X ^a   Fish, Eleanor N ^b,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antiviral; Immune response; Interferons

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; INTERFERON;

ANTIVIRAL ACTIVITY; AVIAN INFLUENZA (H5N1); CORONAVIRINAE; EBOLAVIRUS; EPIDEMIC; HUMAN; IMMUNOCOMPETENT CELL; NONHUMAN; REVIEW; SARS CORONAVIRUS; SIGNAL TRANSDUCTION; VIRUS IMMUNITY; VIRUS INFECTION; ZIKA VIRUS; ANIMAL; COMMUNICABLE DISEASE CONTROL; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INFLUENZA A VIRUS (H5N1); METABOLISM; PHYSIOLOGY; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; COMMUNICABLE DISEASE CONTROL; CORONAVIRUS; DISEASE OUTBREAKS; EBOLAVIRUS; HOST-PATHOGEN INTERACTIONS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INTERFERONS; VIRUS DISEASES; VIRUS REPLICATION;

EID: 85075407523     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2019.101300     Document Type: Review

References (245)

1. Isaacs, A., Lindenmann, J., Virus interference. I. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 147 (1957), 258–267.
2. Au, W.C., Moore, P.A., LaFleur, D.W., Tombal, B., Pitha, P.M., Characterization of the interferon regulatory factor-7 and its potential role in the transcription activation of interferon A genes. J. Biol. Chem. 273 (1998), 29210–29217.
3. Juang, Y.T., Lowther, W., Kellum, M., Au, W.C., Lin, R., Hiscott, J., Pitha, P.M., Primary activation of interferon A and interferon B gene transcription by interferon regulatory factor 3. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 9837–9842.
4. Libermann, T.A., Baltimore, D., Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol. Cell. Biol. 10 (1990), 2327–2334.
5. Matsusaka, T., Fujikawa, K., Nishio, Y., Mukaida, N., Matsushima, K., Kishimoto, T., Akira, S., Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc. Natl. Acad. Sci. U. S. A. 90 (1993), 10193–10197.
6. Sato, M., Hata, N., Asagiri, M., Nakaya, T., Taniguchi, T., Tanaka, N., Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7. FEBS Lett. 441 (1988), 106–110.
7. Falvo, J.V., Parekh, B.S., Lin, C.H., Fraenkel, E., Maniatis, T., Assembly of a functional beta interferon enhanceosome is dependent on ATF-2-c-jun heterodimer orientation. Mol. Cell. Biol. 20 (2000), 4814–4825.
8. Panne, D., Maniatis, T., Harrison, S.C., An atomic model of the interferon-beta enhanceosome. Cell 129 (2007), 1111–1123.
9. Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K., Uematsu, S., Jung, A., Kawai, T., Ishii, K.J., Yamaguchi, O., Otsu, K., Tsujimura, T., Koh, C.S., Reis e Sousa, C., Matsuura, Y., Fujita, T., Akira, S., et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441 (2006), 101–105.
10. Errett, J.S., Suthar, M.S., McMillan, A., Diamond, M.S., Gale, M. Jr, The essential, nonredundant roles of RIG-I and MDA5 in detecting and controlling West Nile virus infection. J. Virol. 87 (2013), 11416–11425.
11. Yan, H., Krishnan, K., Greenlund, A.C., Gupta, S., Lim, J.T., Schreiber, R.D., Schindler, C.W., Krolewski, J.J., Phosphorylated interferon-alpha receptor 1 subunit (IFNaR1) acts as a docking site for the latent form of the 113 kDa STAT2 protein. EMBO J. 15 (1996), 1064–1074.
12. Chen, X., Vinkemeier, U., Zhao, Y., Jeruzalmi, D., Darnell, J.E. Jr., Kuriyan, J., Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell 93 (1998), 827–839.
13. Braunstein, J., Brutsaert, S., Olson, R., Schindler, C., STATs dimerize in the absence of phosphorylation. J. Biol. Chem. 278 (2003), 34133–34140.
14. Fish, E.N., Platanias, L.C., Interferon receptor signaling in malignancy: a network of cellular pathways defining biological outcomes. Mol. Cancer Res. 12 (2014), 1691–1703.
15. Fu, X.Y., Kessler, D.S., Veals, S.A., Levy, D.E., Darnell, J.E. Jr., ISGF3, the transcriptional activator induced by interferon alpha, consists of multiple interacting polypeptide chains. Proc. Natl. Acad. Sci. U. S. A. 87 (1990), 8555–8559.
16. Qureshi, S.A., Salditt-Georgieff, M., Darnell, J.E. Jr., Tyrosine-phosphorylated Stat1 and Stat2 plus a 48-kDa protein all contact DNA in forming interferon-stimulated-gene factor 3. Proc. Natl. Acad. Sci. U. S. A. 92 (1995), 3829–3833.
17. Ehret, G.B., Reichenbach, P., Schindler, U., Horvath, C.M., Fritz, S., Nabholz, M., Bucher, P., DNA binding specificity of different STAT proteins. Comparison of in vitro specificity with natural target sites. J. Biol. Chem. 276 (2001), 6675–6688.
18. Uddin, S., Majchrzak, B., Woodson, J., Arunkumar, P., Alsayed, Y., Pine, R., Young, P.R., Fish, E.N., Platanias, L.C., Activation of the p38 mitogen-activated protein kinase by type I interferons. J. Biol. Chem. 274 (1999), 30127–30131.
19. Dyson, M.H., Thomson, S., Inagaki, M., Goto, H., Arthur, S.J., Nightingale, K., Iborra, F.J., Mahadevan, L.C., MAP kinase-mediated phosphorylation of distinct pools of histone H3 at S10 or S28 via mitogen- and stress-activated kinase 1/2. J. Cell. Sci. 118 (2005), 2247–2259.
20. Kaur, S., Sassano, A., Dolniak, B., Joshi, S., Majchrzak-Kita, B., Baker, D.P., Hay, N., Fish, E.N., Platanias, L.C., Role of the Akt pathway in mRNA translation of interferon-stimulated genes. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 4808–4813.
21. Rusinova, I., Forster, S., Yu, S., Kannan, A., Masse, M., Cumming, H., Chapman, R., Hertzog, P.J., Interferome v2.0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res. 41 (2013), D1040–1046.
22. Mangeat, B., Turelli, P., Caron, G., Friedli, M., Perrin, L., Trono, D., Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424 (2003), 99–103.
23. Yu, Q., Konig, R., Pillai, S., Chiles, K., Kearney, M., Palmer, S., Richman, D., Coffin, J.M., Landau, N.R., Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 11 (2004), 435–442.
24. Neil, S.J., Zang, T., Bieniasz, P.D., Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451 (2008), 425–430.
25. Perez-Caballero, D., Zang, T., Ebrahimi, A., McNatt, M.W., Gregory, D.A., Johnson, M.C., Bieniasz, P.D., Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 139 (2009), 499–511.
26. Kolakofsky, D., Kowalinski, E., Cusack, S., A structure-based model of RIG-I activation. RNA 18 (2012), 2118–2127.
27. Kawai, T., Takahashi, K., Sato, S., Coban, C., Kumar, H., Kato, H., Ishii, K.J., Takeuchi, O., Akira, S., IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat. Immunol. 6 (2005), 981–988.
28. Yoneyama, M., Kikuchi, M., Natsukawa, T., Shinobu, N., Imaizumi, T., Miyagishi, M., Taira, K., Akira, S., Fujita, T., The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5 (2004), 730–737.
29. Oshiumi, H., Miyashita, M., Okamoto, M., Morioka, Y., Okabe, M., Matsumoto, M., Seya, T., DDX60 is involved in RIG-I-dependent and independent antiviral responses, and its function is attenuated by virus-induced EGFR activation. Cell Rep. 11 (2015), 1193–1207.
30. Miyashita, M., Oshiumi, H., Matsumoto, M., Seya, T., DDX60, a DEXD/H box helicase, is a novel antiviral factor promoting RIG-I-like receptor-mediated signaling. Mol. Cell. Biol. 31 (2011), 3802–3819.
31. Min, J.Y., Li, S., Sen, G.C., Krug, R.M., A site on the influenza A virus NS1 protein mediates both inhibition of PKR activation and temporal regulation of viral RNA synthesis. Virology 363 (2007), 236–243.
32. Lemaire, P.A., Anderson, E., Lary, J., Cole, J.L., Mechanism of PKR activation by dsRNA. J. Mol. Biol. 381 (2008), 351–360.
33. Brass, A.L., Huang, I.C., Benita, Y., John, S.P., Krishnan, M.N., Feeley, E.M., Ryan, B.J., Weyer, J.L., van der Weyden, L., Fikrig, E., Adams, D.J., Xavier, R.J., Farzan, M., Elledge, S.J., The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 139 (2009), 1243–1254.
34. Desai, T.M., Marin, M., Chin, C.R., Savidis, G., Brass, A.L., Melikyan, G.B., IFITM3 restricts influenza A virus entry by blocking the formation of fusion pores following virus-endosome hemifusion. PLoS Pathog., 10, 2014, e1004048.
35. Huang, I.C., Bailey, C.C., Weyer, J.L., Radoshitzky, S.R., Becker, M.M., Chiang, J.J., Brass, A.L., Ahmed, A.A., Chi, X., Dong, L., Longobardi, L.E., Boltz, D., Kuhn, J.H., Elledge, S.J., Bavari, S., Denison, M.R., Choe, H., Farzan, M., Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog., 7, 2011, e1001258.
36. Schmid, S., Mordstein, M., Kochs, G., Garcia-Sastre, A., Tenoever, B.R., Transcription factor redundancy ensures induction of the antiviral state. J. Biol. Chem. 285 (2010), 42013–42022.
37. Pine, R., Constitutive expression of an ISGF2/IRF1 transgene leads to interferon-independent activation of interferon-inducible genes and resistance to virus infection. J. Virol. 66 (1992), 4470–4478.
38. Zhao, C., Hsiang, T.Y., Kuo, R.L., Krug, R.M., ISG15 conjugation system targets the viral NS1 protein in influenza A virus-infected cells. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 2253–2258.
39. Malakhova, O.A., Yan, M., Malakhov, M.P., Yuan, Y., Ritchie, K.J., Kim, K.I., Peterson, L.F., Shuai, K., Zhang, D.E., Protein ISGylation modulates the JAK-STAT signaling pathway. Genes Dev. 17 (2003), 455–460.
40. Shi, H.X., Yang, K., Liu, X., Liu, X.Y., Wei, B., Shan, Y.F., Zhu, L.H., Wang, C., Positive regulation of interferon regulatory factor 3 activation by Herc5 via ISG15 modification. Mol. Cell. Biol. 30 (2010), 2424–2436.
41. Espert, L., Degols, G., Gongora, C., Blondel, D., Williams, B.R., Silverman, R.H., Mechti, N., ISG20, a new interferon-induced RNase specific for single-stranded RNA, defines an alternative antiviral pathway against RNA genomic viruses. J. Biol. Chem. 278 (2003), 16151–16158.
42. Zhou, Z., Wang, N., Woodson, S.E., Dong, Q., Wang, J., Liang, Y., Rjinbrand, R., Wei, L., Nichols, J.E., Guo, J.T., Holbrook, M.R., Lemon, S.M., Li, K., Antiviral activities of ISG20 in positive-strand RNA virus infections. Virology 409 (2011), 175–188.
43. Kochs, G., Reichelt, M., Danino, D., Hinshaw, J.E., Haller, O., Assay and functional analysis of dynamin-like Mx proteins. Methods Enzymol. 404 (2005), 632–643.
44. Nigg, P.E., Pavlovic, J., Oligomerization and GTP-binding requirements of MxA for viral target recognition and antiviral activity against influenza A virus. J. Biol. Chem. 290 (2015), 29893–29906.
45. Verhelst, J., Parthoens, E., Schepens, B., Fiers, W., Saelens, X., Interferon-inducible protein Mx1 inhibits influenza virus by interfering with functional viral ribonucleoprotein complex assembly. J. Virol. 86 (2012), 13445–13455.
46. Rusch, L., Zhou, A., Silverman, R.H., Caspase-dependent apoptosis by 2″,5″-oligoadenylate activation of RNase L is enhanced by IFN-beta. J. Interferon Cytokine Res. 20 (2000), 1091–1100.
47. Hovanessian, A.G., Svab, J., Marie, I., Robert, N., Chamaret, S., Laurent, A.G., Characterization of 69- and 100-kDa forms of 2-5A-synthetase from interferon-treated human cells. J. Biol. Chem. 263 (1988), 4945–4949.
48. Li, G., Xiang, Y., Sabapathy, K., Silverman, R.H., An apoptotic signaling pathway in the interferon antiviral response mediated by RNase L and c-Jun NH2-terminal kinase. J. Biol. Chem. 279 (2004), 1123–1131.
49. Zhu, J., Zhang, Y., Ghosh, A., Cuevas, R.A., Forero, A., Dhar, J., Ibsen, M.S., Schmid-Burgk, J.L., Schmidt, T., Ganapathiraju, M.K., Fujita, T., Hartmann, R., Barik, S., Hornung, V., Coyne, C.B., Sarkar, S.N., Antiviral activity of human OASL protein is mediated by enhancing signaling of the RIG-I RNA sensor. Immunity 40 (2014), 936–948.
50. Wang, X., Hinson, E.R., Cresswell, P., The interferon-inducible protein viperin inhibits influenza virus release by perturbing lipid rafts. Cell Host Microbe 2 (2007), 96–105.
51. Laguette, N., Sobhian, B., Casartelli, N., Ringeard, M., Chable-Bessia, C., Segeral, E., Yatim, A., Emiliani, S., Schwartz, O., Benkirane, M., SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 474 (2011), 654–657.
52. Lahouassa, H., Daddacha, W., Hofmann, H., Ayinde, D., Logue, E.C., Dragin, L., Bloch, N., Maudet, C., Bertrand, M., Gramberg, T., Pancino, G., Priet, S., Canard, B., Laguette, N., Benkirane, M., Transy, C., Landau, N.R., Kim, B., Margottin-Goguet, F., SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat. Immunol. 13 (2012), 223–228.
53. Goldstone, D.C., Ennis-Adeniran, V., Hedden, J.J., Groom, H.C., Rice, G.I., Christodoulou, E., Walker, P.A., Kelly, G., Haire, L.F., Yap, M.W., de Carvalho, L.P., Stoye, J.P., Crow, Y.J., Taylor, I.A., Webb, M., HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature 480 (2011), 379–382.
54. Ryoo, J., Choi, J., Oh, C., Kim, S., Seo, M., Kim, S.Y., Seo, D., Kim, J., White, T.E., Brandariz-Nuñez, A., Diaz-Griffero, F., Yun, C.H., Hollenbaugh, J.A., Kim, B., Baek, D., Ahn, K., The ribonuclease activity of SAMHD1 is required for HIV-1 restriction. Nat. Med. 20 (2014), 936–941.
55. Stremlau, M., Perron, M., Lee, M., Li, Y., Song, B., Javanbakht, H., Diaz-Griffero, F., Anderson, D.J., Sundquist, W.I., Sodroski, J., Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 5514–5519.
56. Gack, M.U., Albrecht, R.A., Urano, T., Inn, K.S., Huang, I.C., Carnero, E., Farzan, M., Inoue, S., Jung, J.U., Garcia-Sastre, A., Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe 5 (2009), 439–449.
57. Hayakawa, S., Shiratori, S., Yamato, H., Kameyama, T., Kitatsuji, C., Kashigi, F., Goto, S., Kameoka, S., Fujikura, D., Yamada, T., Mizutani, T., Kazumata, M., Sato, M., Tanaka, J., Asaka, M., Ohba, Y., Miyazaki, T., Imamura, M., Takaoka, A., ZAPS is a potent stimulator of signaling mediated by the RNA helicase RIG-I during antiviral responses. Nat. Immunol. 12 (2011), 37–44.
58. Gao, G., Guo, X., Goff, S.P., Inhibition of retroviral RNA production by ZAP, a CCCH-type zinc finger protein. Science 297 (2002), 1703–1706.
59. Burke, J.D., Platanias, L.C., Fish, E.N., Beta interferon regulation of glucose metabolism is PI3K/Akt dependent and important for antiviral activity against Coxsackie virus B3. J. Virol. 88 (2014), 3485–3495.
60. Essers, M.A., Offner, S., Blanco-Bose, W.E., Waibler, Z., Kalinke, U., Duchosal, M.A., Trumpp, A., IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 458 (2009), 904–908.
61. Sato, T., Onai, N., Yoshihara, H., Arai, F., Suda, T., Ohteki, T., Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion. Nat. Med. 15 (2009), 696–700.
62. Conrady, C.D., Zheng, M., Mandal, N.A., van Rooijen, N., Carr, D.J., IFN-alpha-driven CCL2 production recruits inflammatory monocytes to infection site in mice. Mucosal Immunol. 6 (2013), 45–55.
63. Fujita, H., Asahina, A., Tada, Y., Fujiwara, H., Tamaki, K., Type I interferons inhibit maturation and activation of mouse Langerhans cells. J. Invest. Dermatol. 125 (2005), 126–133.
64. Kim, M.O., Suh, H.S., Brosnan, C.F., Lee, S.C., Regulation of RANTES/CCL5 expression in human astrocytes by interleukin-1 and interferon-beta. J. Neurochem. 90 (2004), 297–308.
65. Menten, P., Proost, P., Struyf, S., Van Coillie, E., Put, W., Lenaerts, J.P., Conings, R., Jaspar, J.M., De Groote, D., Billiau, A., Opdenakker, G., Van Damme, J., Differential induction of monocyte chemotactic protein-3 in mononuclear leukocytes and fibroblasts by interferon-alpha/beta and interferon-gamma reveals MCP-3 heterogeneity. Eur. J. Immunol. 29 (1999), 678–685.
66. Thomas, K.E., Galligan, C.L., Newman, R.D., Fish, E.N., Vogel, S.N., Contribution of interferon-beta to the murine macrophage response to the toll-like receptor 4 agonist, lipopolysaccharide. J. Biol. Chem. 281 (2006), 31119–31130.
67. Antonelli, A., Ferrari, S.M., Fallahi, P., Ghiri, E., Crescioli, C., Romagnani, P., Vitti, P., Serio, M., Ferrannini, E., Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists. Cytokine 50 (2010), 260–267.
68. Coelho, L.F., Magno de Freitas Almeida, G., Mennechet, F.J., Blangy, A., Uze, G., Interferon-alpha and -beta differentially regulate osteoclastogenesis: role of differential induction of chemokine CXCL11 expression. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 11917–11922.
69. Shiow, L.R., Rosen, D.B., Brdickova, N., Xu, Y., An, J., Lanier, L.L., Cyster, J.G., Matloubian, M., CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 440 (2006), 540–544.
70. Seo, S.U., Kwon, H.J., Ko, H.J., Byun, Y.H., Seong, B.L., Uematsu, S., Akira, S., Kweon, M.N., Type I interferon signaling regulates Ly6C(hi) monocytes and neutrophils during acute viral pneumonia in mice. PLoS Pathog., 7, 2011, e1001304.
71. Stock, A.T., Smith, J.M., Carbone, F.R., Type I IFN suppresses Cxcr2 driven neutrophil recruitment into the sensory ganglia during viral infection. J. Exp. Med. 211 (2014), 751–759.
72. Xin, L., Vargas-Inchaustegui, D.A., Raimer, S.S., Kelly, B.C., Hu, J., Zhu, L., Sun, J., Soong, L., Type I IFN receptor regulates neutrophil functions and innate immunity to Leishmania parasites. J. Immunol. 184 (2010), 7047–7056.
73. Lee, P.Y., Li, Y., Kumagai, Y., Xu, Y., Weinstein, J.S., Kellner, E.S., Nacionales, D.C., Butfiloski, E.J., van Rooijen, N., Akira, S., Sobel, E.S., Satoh, M., Reeves, W.H., Type I interferon modulates monocyte recruitment and maturation in chronic inflammation. Am. J. Pathol. 175 (2009), 2023–2033.
74. Murooka, T.T., Rahbar, R., Platanias, L.C., Fish, E.N., CCL5-mediated T-cell chemotaxis involves the initiation of mRNA translation through mTOR/4E-BP1. Blood 111 (2008), 4892–4901.
75. Colvin, R.A., Campanella, G.S., Sun, J., Luster, A.D., Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. J. Biol. Chem. 279 (2004), 30219–30227.
76. Carr, M.W., Roth, S.J., Luther, E., Rose, S.S., Springer, T.A., Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc. Natl. Acad. Sci. U. S. A. 91 (1994), 3652–3656.
77. Zucchetto, A., Tripodo, C., Benedetti, D., Deaglio, S., Gaidano, G., Del Poeta, G., Gattei, V., Monocytes/macrophages but not T lymphocytes are the major targets of the CCL3/CCL4 chemokines produced by CD38(+)CD49d(+) chronic lymphocytic leukaemia cells. Br. J. Haematol. 150 (2010), 111–113.
78. Sakamoto, E., Hato, F., Kato, T., Sakamoto, C., Akahori, M., Hino, M., Kitagawa, S., Type I and type II interferons delay human neutrophil apoptosis via activation of STAT3 and up-regulation of cellular inhibitor of apoptosis 2. J. Leukoc. Biol. 78 (2005), 301–309.
79. Hunter, C.A., Gabriel, K.E., Radzanowski, T., Neyer, L.E., Remington, J.S., Type I interferons enhance production of IFN-gamma by NK cells. Immunol. Lett. 59 (1997), 1–5.
80. Nguyen, K.B., Salazar-Mather, T.P., Dalod, M.Y., Van Deusen, J.B., Wei, X.Q., Liew, F.Y., Caligiuri, M.A., Durbin, J.E., Biron, C.A., Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. J. Immunol. 169 (2002), 4279–4287.
81. Lee, C.K., Rao, D.T., Gertner, R., Gimeno, R., Frey, A.B., Levy, D.E., Distinct requirements for IFNs and STAT1 in NK cell function. J. Immunol. 165 (2000), 3571–3577.
82. Martinez, J., Huang, X., Yang, Y., Direct action of type I IFN on NK cells is required for their activation in response to vaccinia viral infection in vivo. J. Immunol. 180 (2008), 1592–1597.
83. Swann, J.B., Hayakawa, Y., Zerafa, N., Sheehan, K.C., Scott, B., Schreiber, R.D., Hertzog, P., Smyth, M.J., Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J. Immunol. 178 (2007), 7540–7549.
84. Kirou, K.A., Vakkalanka, R.K., Butler, M.J., Crow, M.K., Induction of Fas ligand-mediated apoptosis by interferon-alpha. Clin. Immunol. 95 (2000), 218–226.
85. Yanguez, E., Garcia-Culebras, A., Frau, A., Llompart, C., Knobeloch, K.P., Gutierrez-Erlandsson, S., Garcia-Sastre, A., Esteban, M., Nieto, A., Guerra, S., Correction: ISG15 regulates peritoneal macrophages functionality against viral infection. PLoS Pathog., 12, 2016, e1005969.
86. Pogue, S.L., Preston, B.T., Stalder, J., Bebbington, C.R., Cardarelli, P.M., The receptor for type I IFNs is highly expressed on peripheral blood B cells and monocytes and mediates a distinct profile of differentiation and activation of these cells. J. Interferon Cytokine Res. 24 (2004), 131–139.
87. Dauer, M., Schad, K., Junkmann, J., Bauer, C., Herten, J., Kiefl, R., Schnurr, M., Endres, S., Eigler, A., IFN-alpha promotes definitive maturation of dendritic cells generated by short-term culture of monocytes with GM-CSF and IL-4. J. Leukoc. Biol. 80 (2006), 278–286.
88. Luft, T., Pang, K.C., Thomas, E., Hertzog, P., Hart, D.N., Trapani, J., Cebon, J., Type I IFNs enhance the terminal differentiation of dendritic cells. J. Immunol. 161 (1998), 1947–1953.
89. Dauer, M., Obermaier, B., Herten, J., Haerle, C., Pohl, K., Rothenfusser, S., Schnurr, M., Endres, S., Eigler, A., Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J. Immunol. 170 (2003), 4069–4076.
90. Paquette, R.L., Hsu, N.C., Kiertscher, S.M., Park, A.N., Tran, L., Roth, M.D., Glaspy, J.A., Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J. Leukoc. Biol. 64 (1998), 358–367.
91. Gautier, G., Humbert, M., Deauvieau, F., Scuiller, M., Hiscott, J., Bates, E.E., Trinchieri, G., Caux, C., Garrone, P., A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J. Exp. Med. 201 (2005), 1435–1446.
92. Simmons, D.P., Wearsch, P.A., Canaday, D.H., Meyerson, H.J., Liu, Y.C., Wang, Y., Boom, W.H., Harding, C.V., Type I IFN drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing. J. Immunol. 188 (2012), 3116–3126.
93. Montoya, M., Schiavoni, G., Mattei, F., Gresser, I., Belardelli, F., Borrow, P., Tough, D.F., Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 99 (2002), 3263–3271.
94. Honda, K., Yanai, H., Negishi, H., Asagiri, M., Sato, M., Mizutani, T., Shimada, N., Ohba, Y., Takaoka, A., Yoshida, N., Taniguchi, T., IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434 (2005), 772–777.
95. Izaguirre, A., Barnes, B.J., Amrute, S., Yeow, W.S., Megjugorac, N., Dai, J., Feng, D., Chung, E., Pitha, P.M., Fitzgerald-Bocarsly, P., Comparative analysis of IRF and IFN-alpha expression in human plasmacytoid and monocyte-derived dendritic cells. J. Leukoc. Biol. 74 (2003), 1125–1138.
96. Huber, J.P., Farrar, J.D., Regulation of effector and memory T-cell functions by type I interferon. Immunology 132 (2011), 466–474.
97. Curtsinger, J.M., Valenzuela, J.O., Agarwal, P., Lins, D., Mescher, M.F., Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J. Immunol. 174 (2005), 4465–4469.
98. Kolumam, G.A., Thomas, S., Thompson, L.J., Sprent, J., Murali-Krishna, K., Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J. Exp. Med. 202 (2005), 637–650.
99. Aichele, P., Unsoeld, H., Koschella, M., Schweier, O., Kalinke, U., Vucikuja, S., CD8 T cells specific for lymphocytic choriomeningitis virus require type I IFN receptor for clonal expansion. J. Immunol. 176 (2006), 4525–4529.
100. Thompson, L.J., Kolumam, G.A., Thomas, S., Murali-Krishna, K., Innate inflammatory signals induced by various pathogens differentially dictate the IFN-I dependence of CD8 T cells for clonal expansion and memory formation. J. Immunol. 177 (2006), 1746–1754.
101. Agarwal, P., Raghavan, A., Nandiwada, S.L., Curtsinger, J.M., Bohjanen, P.R., Mueller, D.L., Mescher, M.F., Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8 T cell effector function and memory. J. Immunol. 183 (2009), 1695–1704.
102. Le Bon, A., Thompson, C., Kamphuis, E., Durand, V., Rossmann, C., Kalinke, U., Tough, D.F., Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J. Immunol. 176 (2006), 2074–2078.
103. Huber, J.P., Ramos, H.J., Gill, M.A., Farrar, J.D., Cutting edge: type I IFN reverses human Th2 commitment and stability by suppressing GATA3. J. Immunol. 185 (2010), 813–817.
104. Moschen, A.R., Geiger, S., Krehan, I., Kaser, A., Tilg, H., Interferon-alpha controls IL-17 expression in vitro and in vivo. Immunobiology 213 (2008), 779–787.
105. Deonarain, R., Verma, A., Porter, A.C., Gewert, D.R., Platanias, L.C., Fish, E.N., Critical roles for IFN-beta in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor alpha. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 13453–13458.
106. Braun, D., Caramalho, I., Demengeot, J., IFN-alpha/beta enhances BCR-dependent B cell responses. Int. Immunol. 14 (2002), 411–419.
107. Evans, S.S., Collea, R.P., Appenheimer, M.M., Gollnick, S.O., Interferon-alpha induces the expression of the L-selectin homing receptor in human B lymphoid cells. J. Cell Biol. 123 (1993), 1889–1898.
108. Hamilton, J.A., Wu, Q., Yang, P., Luo, B., Liu, S., Hong, H., Li, J., Walter, M.R., Fish, E.N., Hsu, H.C., Mountz, J.D., Cutting edge: endogenous IFN-Β regulates survival and development of transitional B cells. J. Immunol. 199 (2017), 2618–2623.
109. Yao, Y., Richman, L., Higgs, B.W., Morehouse, C.A., de los Reyes, M., Brohawn, P., Zhang, J., White, B., Coyle, A.J., Kiener, P.A., Jallal, B., Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 60 (2009), 1785–1796.
110. Litinskiy, M.B., Nardelli, B., Hilbert, D.M., He, B., Schaffer, A., Casali, P., Cerutti, A., DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat. Immunol. 3 (2002), 822–829.
111. Joo, H., Coquery, C., Xue, Y., Gayet, I., Dillon, S.R., Punaro, M., Zurawski, G., Banchereau, J., Pascual, V., Oh, S., Serum from patients with SLE instructs monocytes to promote IgG and IgA plasmablast differentiation. J. Exp. Med. 209 (2012), 1335–1348.
112. Castigli, E., Wilson, S.A., Scott, S., Dedeoglu, F., Xu, S., Lam, K.P., Bram, R.J., Jabara, H., Geha, R.S., TACI and BAFF-R mediate isotype switching in B cells. J. Exp. Med. 201 (2005), 35–39.
113. Castigli, E., Scott, S., Dedeoglu, F., Bryce, P., Jabara, H., Bhan, A.K., Mizoguchi, E., Geha, R.S., Impaired IgA class switching in APRIL-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 3903–3908.
114. Jego, G., Palucka, A.K., Blanck, J.P., Chalouni, C., Pascual, V., Banchereau, J., Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19 (2003), 225–234.
115. Fros, J.J., Liu, W.J., Prow, N.A., Geertsema, C., Ligtenberg, M., Vanlandingham, D.L., Schnettier, E., Vlak, J.M., Suhrbier, A., Khromykh, A.A., Pijlman, G.P., Chikungunya virus nonstructural protein 2 inhibits type I/II interferon-stimulated JAK-STAT signaling. J. Virol. 84 (2010), 10877–10887.
116. Feng, Q., Langereis, M.A., Lork, M., Nguyen, M., Hato, S.V., Lanke, K., Emdad, L., Bhoopathi, P., Fisher, P.B., Lloyd, R.E., van Kuppeveld, F.J., Enterovirus 2Apro targets MDA5 and MAVS in infected cells. J. Virol. 88 (2014), 3369–3378.
117. Mukherjee, A., Morosky, S.A., Delorme-Axford, E., Dybdahl-Sissoko, N., Oberste, M.S., Wang, T., Coyne, C.B., The coxsackievirus B 3C protease cleaves MAVS and TRIF to attenuate host type I interferon and apoptotic signaling. PLoS Pathog., 7, 2011, e1001311.
118. Munoz-Jordan, J.L., Sanchez-Burgos, G.G., Laurent-Rolle, M., Garcia-Sastre, A., Inhibition of interferon signaling by dengue virus. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 14333–14338.
119. Munoz-Jordan, J.L., Laurent-Rolle, M., Ashour, J., Martinez-Sobrido, L., Ashok, M., Lipkin, W.I., Garcia-Sastre, A., Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J. Virol. 79 (2005), 8004–8013.
120. Rodriguez-Madoz, J.R., Belicha-Villanueva, A., Bernal-Rubio, D., Ashour, J., Ayllon, J., Fernandez-Sesma, A., Inhibition of the type I interferon response in human dendritic cells by dengue virus infection requires a catalytically active NS2B3 complex. J. Virol. 84 (2010), 9760–9774.
121. Mazzon, M., Jones, M., Davidson, A., Chain, B., Jacobs, M., Dengue virus NS5 inhibits interferon-alpha signaling by blocking signal transducer and activator of transcription 2 phosphorylation. J. Infect. Dis. 200 (2009), 1261–1270.
122. Zhang, A.P., Bornholdt, Z.A., Liu, T., Abelson, D.M., Lee, D.E., Li, S., Woods, V.L. Jr., Saphire, E.O., The ebola virus interferon antagonist VP24 directly binds STAT1 and has a novel, pyramidal fold. PLoS Pathog., 8, 2012, e1002550.
123. Reid, S.P., Leung, L.W., Hartman, A.L., Martinez, O., Shaw, M.L., Carbonnelle, C., Volchkov, V.E., Nichol, S.T., Basler, C.F., Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J. Virol. 80 (2006), 5156–5167.
124. Basler, C.F., Wang, X., Muhlberger, E., Volchkov, V., Paragas, J., Klenk, H.D., Garcia-Sastre, A., Palese, P., The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 12289–12294.
125. Cardenas, W.B., Loo, Y.M., Gale, M. Jr., Hartman, A.L., Kimberlin, C.R., Martinez-Sobrido, L., Saphire, E.O., Basler, C.F., Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J. Virol. 80 (2006), 5168–5178.
126. Bentz, G.L., Liu, R., Hahn, A.M., Shackelford, J., Pagano, J.S., Epstein-Barr virus BRLF1 inhibits transcription of IRF3 and IRF7 and suppresses induction of interferon-beta. Virology 402 (2010), 121–128.
127. Hahn, A.M., Huye, L.E., Ning, S., Webster-Cyriaque, J., Pagano, J.S., Interferon regulatory factor 7 is negatively regulated by the Epstein-Barr virus immediate-early gene, BZLF-1. J. Virol. 79 (2005), 10040–10052.
128. Wu, L., Fossum, E., Joo, C.H., Inn, K.S., Shin, Y.C., Johannsen, E., Hutt-Fletcher, L.M., Hass, J., Jung, J.U., Epstein-Barr virus LF2: an antagonist to type I interferon. J. Virol. 83 (2009), 1140–1146.
129. Jiang, J., Tang, H., Mechanism of inhibiting type I interferon induction by hepatitis B virus X protein. Protein Cell 1 (2010), 1106–1117.
130. Chen, J., Wu, M., Zhang, X., Zhang, W., Zhang, Z., Chen, L., He, J., Zheng, Y., Chen, C., Wang, F., Hu, Y., Zhou, X., Wang, C., Xu, Y., Lu, M., Yuan, Z., Hepatitis B virus polymerase impairs interferon-alpha-induced STAT activation through inhibition of importin-alpha5 and protein kinase C-delta. Hepatology 57 (2013), 470–482.
131. Wang, H., Ryu, W.S., Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: implications for immune evasion. PLoS Pathog., 6, 2010, e1000986.
132. Bode, J.G., Ludwig, S., Ehrhardt, C., Albrecht, U., Erhardt, A., Schaper, F., Heinrich, P.C., Häussinger, D., IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J. 17 (2003), 488–490.
133. Taylor, D.R., Shi, S.T., Romano, P.R., Barber, G.N., Lai, M.M., Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285 (1999), 107–110.
134. Baril, M., Racine, M.E., Penin, F., Lamarre, D., MAVS dimer is a crucial signaling component of innate immunity and the target of hepatitis C virus NS3/4A protease. J. Virol. 83 (2009), 1299–1311.
135. Li, K., Foy, E., Ferreon, J.C., Nakamura, M., Ferreon, A.C., Ikeda, M., Ray, S.C., Gale, M. Jr., Lemon, S.M., Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 2992–2997.
136. Kumthip, K., Chusri, P., Jilg, N., Zhao, L., Fusco, D.N., Zhao, H., Goto, K., Cheng, D., Schaefer, E.A., Zhang, L., Pantip, C., Thongsawat, S., O'Brien, A., Peng, L.F., Maneekarn, N., Chung, R.T., Lin, W., Hepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signaling. J. Virol. 86 (2012), 8581–8591.
137. Gale, M. Jr, Blakely, C.M., Kwieciszewski, B., Tan, S.L., Dossett, M., Tang, N.M., Tang, N.M., Korth, M.J., Polyak, S.J., Gretch, D.R., Katze, M.G., Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol. Cell. Biol. 18 (1998), 5208–5218.
138. Paulus, C., Krauss, S., Nevels, M., A human cytomegalovirus antagonist of type I IFN-dependent signal transducer and activator of transcription signaling. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 3840–3845.
139. Huh, Y.H., Kim, Y.E., Kim, E.T., Park, J.J., Song, M.J., Zhu, H., Hayward, G.S., Ahn, J.H., Binding STAT2 by the acidic domain of human cytomegalovirus IE1 promotes viral growth and is negatively regulated by SUMO. J. Virol. 82 (2008), 10444–10454.
140. Taylor, R.T., Bresnahan, W.A., Human cytomegalovirus immediate-early 2 gene expression blocks virus-induced beta interferon production. J. Virol. 79 (2005), 3873–3877.
141. Marshall, E.E., Bierle, C.J., Brune, W., Geballe, A.P., Essential role for either TRS1 or IRS1 in human cytomegalovirus replication. J. Virol. 83 (2009), 4112–4120.
142. Kim, Y.J., Kim, E.T., Kim, Y.E., Lee, M.K., Kwon, K.M., Kim, K.I., Stamminger, T., Ahn, J.H., Consecutive inhibition of ISG15 expression and ISGylation by cytomegalovirus regulators. PLoS Pathog., 12, 2016, e1005850.
143. Cai, R., Carpick, B., Chun, R.F., Jeang, K.T., Williams, B.R., HIV-I TAT inhibits PKR activity by both RNA-dependent and RNA-independent mechanisms. Arch. Biochem. Biophys. 373 (2000), 361–367.
144. Stopak, K., de Noronha, C., Yonemoto, W., Greene, W.C., HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12 (2003), 591–601.
145. Bartlett, E.J., Cruz, A.M., Esker, J., Castano, A., Schomacker, H., Surman, S.R., Hennessey, M., Boonyaratanakornkit, J., Pickles, R.J., Collins, P.L., Murphy, B.R., Schmidt, A.C., Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates. J. Virol. 82 (2008), 8965–8977.
146. Schaap-Nutt, A., D'Angelo, C., Scull, M.A., Amaro-Carambot, E., Nishio, M., Pickles, R.J., Collins, P.L., Murphy, B.R., Schmidt, A.C., Human parainfluenza virus type 2 V protein inhibits interferon production and signaling and is required for replication in non-human primates. Virology 397 (2010), 285–298.
147. Nees, M., Geoghegan, J.M., Hyman, T., Frank, S., Miller, L., Woodworth, C.D., Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J. Virol. 75 (2001), 4283–4296.
148. Ronco, L.V., Karpova, A.Y., Vidal, M., Howley, P.M., Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev. 12 (1998), 2061–2072.
149. Spann, K.M., Tran, K.C., Collins, P.L., Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-kappaB, and proinflammatory cytokines. J. Virol. 79 (2005), 5353–5362.
150. Kotla, S., Peng, T., Bumgarner, R.E., Gustin, K.E., Attenuation of the type I interferon response in cells infected with human rhinovirus. Virology 374 (2008), 399–410.
151. Paladino, P., Collins, S.E., Mossman, K.L., Cellular localization of the herpes simplex virus ICP0 protein dictates its ability to block IRF3-mediated innate immune responses. PLoS One, 5, 2010, e10428.
152. Johnson, K.E., Song, B., Knipe, D.M., Role for herpes simplex virus 1 ICP27 in the inhibition of type I interferon signaling. Virology 374 (2008), 487–494.
153. He, B., Gross, M., Roizman, B., The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc. Natl. Acad. Sci. U. S. A. 94 (1997), 843–848.
154. Sanchez, R., Mohr, I., Inhibition of cellular 2″-5″ oligoadenylate synthetase by the herpes simplex virus type 1 Us11 protein. J. Virol. 81 (2007), 3455–3464.
155. Jia, D., Rahbar, R., Chan, R.W., Lee, S.M., Chan, M.C., Wang, B.X., Baker, D.P., Sun, B., Peiris, J.S., Nicholls, J.M., Fish, E.N., Influenza virus non-structural protein 1 (NS1) disrupts interferon signaling. PLoS One, 5, 2010, e13927.
156. Mibayashi, M., Martinez-Sobrido, L., Loo, Y.M., Cardenas, W.B., Gale, M. Jr., Garcia-Sastre, A., Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus. J. Virol. 81 (2007), 514–524.
157. Twu, K.Y., Noah, D.L., Rao, P., Kuo, R.L., Krug, R.M., The CPSF30 binding site on the NS1A protein of influenza A virus is a potential antiviral target. J. Virol. 80 (2006), 3957–3965.
158. Bergmann, M., Garcia-Sastre, A., Carnero, E., Pehamberger, H., Wolff, K., Palese, P., Muster, T., Influenza virus NS1 protein counteracts PKR-mediated inhibition of replication. J. Virol. 74 (2000), 6203–6206.
159. Chen, Z., Li, Y., Krug, R.M., Influenza A virus NS1 protein targets poly(A)-binding protein II of the cellular 3″-end processing machinery. EMBO J. 18 (1999), 2273–2283.
160. Min, J.Y., Krug, R.M., The primary function of RNA binding by the influenza A virus NS1 protein in infected cells: Inhibiting the 2″-5″ oligo (A) synthetase/RNase L pathway. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 7100–7105.
161. Dauber, B., Schneider, J., Wolff, T., Double-stranded RNA binding of influenza B virus nonstructural NS1 protein inhibits protein kinase R but is not essential to antagonize production of alpha/beta interferon. J. Virol. 80 (2006), 11667–11677.
162. Lin, C.W., Cheng, C.W., Yang, T.C., Li, S.W., Cheng, M.H., Wan, L., Lin, Y.J., Lai, C.H., Lin, W.Y., Kao, M.C., Interferon antagonist function of Japanese encephalitis virus NS4A and its interaction with DEAD-box RNA helicase DDX42. Virus Res. 137 (2008), 49–55.
163. Lin, R.J., Chang, B.L., Yu, H.P., Liao, C.L., Lin, Y.L., Blocking of interferon-induced Jak-Stat signaling by Japanese encephalitis virus NS5 through a protein tyrosine phosphatase-mediated mechanism. J. Virol. 80 (2006), 5908–5918.
164. Yang, T.C., Li, S.W., Lai, C.C., Lu, K.Z., Chiu, M.T., Hsieh, T.H., Wan, L., Lin, C.W., Proteomic analysis for Type I interferon antagonism of Japanese encephalitis virus NS5 protein. Proteomics 13 (2013), 3442–3456.
165. Hastie, K.M., Kimberlin, C.R., Zandonatti, M.A., MacRae, I.J., Saphire, E.O., Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3″ to 5″ exonuclease activity essential for immune suppression. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 2396–2401.
166. Martinez-Sobrido, L., Giannakas, P., Cubitt, B., Garcia-Sastre, A., de la Torre, J.C., Differential inhibition of type I interferon induction by arenavirus nucleoproteins. J. Virol. 81 (2007), 12696–12703.
167. Zhou, S., Cerny, A.M., Zacharia, A., Fitzgerald, K.A., Kurt-Jones, E.A., Finberg, R.W., Induction and inhibition of type I interferon responses by distinct components of lymphocytic choriomeningitis virus. J. Virol. 84 (2010), 9452–9462.
168. Kash, J.C., Muhlberger, E., Carter, V., Grosch, M., Perwitasari, O., Proll, S.C., Thomas, M.J., Weber, F., Klenk, H.D., Katze, M.G., Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J. Virol. 80 (2006), 3009–3020.
169. Ramanan, P., Edwards, M.R., Shabman, R.S., Leung, D.W., Endlich-Frazier, A.C., Borek, D.M., Otwinowski, Z., Borek, D.M., Liu, G., Huh, J., Basler, C.F., Amarasinghe, G.K., Structural basis for Marburg virus VP35-mediated immune evasion mechanisms. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 20661–20666.
170. Valmas, C., Basler, C.F., Marburg virus VP40 antagonizes interferon signaling in a species-specific manner. J. Virol. 85 (2011), 4309–4317.
171. Takayama, I., Sato, H., Watanabe, A., Omi-Furutani, M., Sugai, A., Kanki, K., Yoneda, M., Kai, C., The nucleocapsid protein of measles virus blocks host interferon response. Virology 424 (2012), 45–55.
172. Ramachandran, A., Parisien, J.P., Horvath, C.M., STAT2 is a primary target for measles virus V protein-mediated alpha/beta interferon signaling inhibition. J. Virol. 82 (2008), 8330–8338.
173. Yang, Y., Zhang, L., Geng, H., Deng, Y., Huang, B., Guo, Y., Zhao, Z., Tan, W., The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists. Protein Cell 4 (2013), 951–961.
174. Niemeyer, D., Zillinger, T., Muth, D., Zielecki, F., Horvath, G., Suliman, T., Barchet, W., Weber, F., Dorsten, C., Müller, M.A., Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist. J. Virol. 87 (2013), 12489–12495.
175. Kubota, T., Yokosawa, N., Yokota, S., Fujii, N., Tashiro, M., Kato, A., Mumps virus V protein antagonizes interferon without the complete degradation of STAT1. J. Virol. 79 (2005), 4451–4459.
176. Shaw, M.L., Garcia-Sastre, A., Palese, P., Basler, C.F., Nipah virus V and W proteins have a common STAT1-binding domain yet inhibit STAT1 activation from the cytoplasmic and nuclear compartments, respectively. J. Virol. 78 (2004), 5633–5641.
177. Brzozka, K., Finke, S., Conzelmann, K.K., Inhibition of interferon signaling by rabies virus phosphoprotein P: activation-dependent binding of STAT1 and STAT2. J. Virol. 80 (2006), 2675–2683.
178. Brzozka, K., Finke, S., Conzelmann, K.K., Identification of the rabies virus alpha/beta interferon antagonist: phosphoprotein P interferes with phosphorylation of interferon regulatory factor 3. J. Virol. 79 (2005), 7673–7681.
179. Lieu, K.G., Brice, A., Wiltzer, L., Hirst, B., Jans, D.A., Blondel, D., Moseley, G.W., The rabies virus interferon antagonist P protein interacts with activated STAT3 and inhibits Gp130 receptor signaling. J. Virol. 87 (2013), 8261–8265.
180. Barro, M., Patton, J.T., Rotavirus NSP1 inhibits expression of type I interferon by antagonizing the function of interferon regulatory factors IRF3, IRF5, and IRF7. J. Virol. 81 (2007), 4473–4481.
181. Graff, J.W., Ettayebi, K., Hardy, M.E., Rotavirus NSP1 inhibits NFkappaB activation by inducing proteasome-dependent degradation of beta-TrCP: a novel mechanism of IFN antagonism. PLoS Pathog., 5, 2009, e1000280.
182. Siu, K.L., Chan, C.P., Kok, K.H., Chiu-Yat Woo, P., Jin, D.Y., Suppression of innate antiviral response by severe acute respiratory syndrome coronavirus M protein is mediated through the first transmembrane domain. Cell. Mol. Immunol. 11 (2014), 141–149.
183. Siu, K.L., Kok, K.H., Ng, M.H., Poon, V.K., Yuen, K.Y., Zheng, B.J., Jin, D.Y., Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3.TANK.TBK1/IKKepsilon complex. J. Biol. Chem. 284 (2009), 16202–16209.
184. Kamitani, W., Narayanan, K., Huang, C., Lokugamage, K., Ikegami, T., Ito, N., Kubo, H., Makino, S., Severe acute respiratory syndrome coronavirus nsp1 protein suppresses host gene expression by promoting host mRNA degradation. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 12885–12890.
185. Narayanan, K., Huang, C., Lokugamage, K., Kamitani, W., Ikegami, T., Tseng, C.T., Makino, S., Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon, in infected cells. J. Virol. 82 (2008), 4471–4479.
186. Wathelet, M.G., Orr, M., Frieman, M.B., Baric, R.S., Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain. J. Virol. 81 (2007), 11620–11633.
187. Devaraj, S.G., Wang, N., Chen, Z., Chen, Z., Tseng, M., Barretto, N., Lin, R., Peters, C.J., Tseng, C.T., Baker, S.C., Li, K., Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus. J. Biol. Chem. 282 (2007), 32208–32221.
188. Frieman, M., Yount, B., Heise, M., Kopecky-Bromberg, S.A., Palese, P., Baric, R.S., Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane. J. Virol. 81 (2007), 9812–9824.
189. Xiang, Y., Condit, R.C., Vijaysri, S., Jacobs, B., Williams, B.R., Silverman, R.H., Blockade of interferon induction and action by the E3L double-stranded RNA binding proteins of vaccinia virus. J. Virol. 76 (2002), 5251–5259.
190. Davies, M.V., Chang, H.W., Jacobs, B.L., Kaufman, R.J., The E3L and K3L vaccinia virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by different mechanisms. J. Virol. 67 (1993), 1688–1692.
191. Alcami, A., Symons, J.A., Smith, G.L., The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J. Virol. 74 (2000), 11230–11239.
192. Laurent-Rolle, M., Boer, E.F., Lubick, K.J., Wolfinbarger, J.B., Carmody, A.B., Rockx, B., Liu, W., Ashour, J., Shupert, W.L., Holbrook, M.R., Barrett, A.D., Mason, P.W., Bloom, M.E., Garcia-Sastre, A., Khromykh, A.A., Best, S.M., The NS5 protein of the virulent West Nile virus NY99 strain is a potent antagonist of type I interferon-mediated JAK-STAT signaling. J. Virol. 84 (2010), 3503–3515.
193. Guo, J.T., Hayashi, J., Seeger, C., West Nile virus inhibits the signal transduction pathway of alpha interferon. J. Virol. 79 (2005), 1343–1350.
194. Laurent-Rolle, M., Morrison, J., Rajsbaum, R., Macleod, J.M., Pisanelli, G., Pham, A., Miorin, J.Ayllon L., tenOever, B.R., Garcia-Sastre, A., The interferon signaling antagonist function of yellow fever virus NS5 protein is activated by type I interferon. Cell Host Microbe 16 (2014), 314–327.
195. Kumar, A., Hou, S., Airo, A.M., Limonta, D., Mancinelli, V., Branton, W., Power, C., Hobman, T.C., Zika virus inhibits type-I interferon production and downstream signaling. EMBO Rep. 17 (2016), 1766–1775.
196. World Heath Organization. https://www.who.int, 2019 (accessed July 31, 2019).
197. Negro, F., Adverse effects of drugs in the treatment of viral hepatitis. Best Pract. Res. Clin. Gastroenterol. 24 (2010), 183–192.
198. Dhillon, S., Kaker, A., Dosanjh, A., Japra, D., Vanthiel, D.H., Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C. Dig. Dis. Sci. 55 (2010), 1785–1790.
199. Kim, S.R., Imoto, S., Mita, K., Taniguchi, M., Sasase, N., Muramatsu, A., Kudo, M., Kitai, S., El-Shamy, A., Hotta, H., Hayashi, Y., Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis. Digestion 79 (2009), 36–39.
200. Yamazaki, M., Sato, A., Takeda, T., Komatsu, M., Distinct clinical courses in type 1 diabetes mellitus induced by peg-interferon-alpha treatment for chronic hepatitis C. Int. Med. 49 (2010), 403–407.
201. Formann, E., Jessner, W., Bennett, L., Ferenci, P., Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. J. Viral Hepat. 10 (2003), 271–276.
202. Mangia, A., Santoro, R., Minerva, N., Ricci, G.L., Carretta, V., Persico, M., Vinelli, F., Scotto, G., Bacca, D., Annese, M., Romano, M., Zechini, F., Sogari, F., Spirito, F., Andriulli, A., Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 352 (2005), 2609–2617.
203. Shiffman, M.L., Suter, F., Bacon, B.R., Nelson, D., Harley, H., Sola, R., Shafran, S.D., Barange, K., Lin, A., Soman, A., Zeuzem, S., ACCELERATE Investigators, Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 357 (2007), 124–134.
204. Yu, M.L., Dai, C.Y., Huang, J.F., Hou, N.J., Lee, L.P., Hsieh, M.Y., Chiu, C.F., Lin, Z.Y., Chen, S.C., Wang, L.Y., Chang, W.Y., Chuang, W.L., A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 56 (2007), 553–559.
205. Dalgard, O., Bjoro, K., Ring-Larsen, H., Bjornsson, E., Holberg-Petersen, M., Skovlund, E., Reichard, O., Myrvang, B., Sundelof, B., Ritland, S., Hellum, K., Frydén, A., Florholmen, J., Verbaan, H., North-C Group, Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 47 (2008), 35–42.
206. Varghese, R., Al-Khaldi, J., Asker, H., Fadili, A.A., Al Ali, J., Hassan, F.A., Treatment of chronic hepatitis C genotype 4 with peginterferon alpha-2a plus ribavirin. Hepatogastroenterology 56 (2009), 218–222.
207. Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V.K., Shiffman, M., Reindollar, R., Goodman, Z.D., Koury, K., Ling, M., Albrecht, J.K., Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001), 958–965.
208. Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinos, G., Goncales, F.L. Jr., Haussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J., Yu, J., Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347 (2002), 975–982.
209. Hadziyannis, S.J., Sette, H. Jr., Morgan, T.R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H. Jr., Bernstein, D., Rizzetto, M., Zeuzem, S., Pockros, P.J., Lin, A., Ackrill, A.M., PEGASYS International Study Group, Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140 (2004), 346–355.
210. Legrand-Abravanel, F., Colson, P., Leguillou-Guillemette, H., Alric, L., Ravaux, I., Lunel-Fabiani, F., Bouviers-Alias, M., Trimoulet, P., Chaix, M.L., Hezode, C., Foucher, J., Fontaine, H., Roque-Afonso, A.M., Gassin, M., Schvoerer, E., Gaudy, C., Roche, B., Doffoël, M., D'Alteroche, L., Vallet, S., Baazia, Y., Pozzetto, B., Thibault, V., Nousbaum, J.B., Roulot, D., Coppere, H., Poynard, T., Payan, C., Izopet, J., Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. J. Med. Virol. 81 (2009), 2029–2035.
211. Inoue, Y., Hiramatsu, N., Oze, T., Yakushijin, T., Mochizuki, K., Hagiwara, H., Oshita, M., Mita, E., Fukui, H., Inada, M., Tamura, S., Yoshihara, H., Hayashi, E., Inoue, A., Imai, Y., Kato, M., Miyagi, T., Hohsui, A., Ishida, H., Kiso, S., Kanto, T., Kasahara, A., Takehara, T., Hayashi, N., Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses. J. Viral Hepat. 17 (2010), 336–344.
212. Poordad, F., Reddy, K.R., Martin, P., Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin. Infect. Dis. 46 (2008), 78–84.
213. Federico, A., Masarone, M., Romano, M., Dallio, M., Rosato, V., Persico, M., Rapid virological response represents the highest prediction factor of response to antiviral treatment in HCV-related chronic hepatitis: a multicenter retrospective study. Hepat. Mon., 15, 2015, e18640.
214. Kim, K.A., Lin, W., Tai, A.W., Shao, R.X., Weinberg, E., De Sa Borges, C.B., Bhan, A.K., Zheng, H., Kamegaya, Y., Chung, R.T., Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection. J. Hepatol. 50 (2009), 705–711.
215. Persico, M., Capasso, M., Russo, R., Persico, E., Croce, L., Tiribelli, C., Iolascon, A., Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C. Gut 57 (2008), 507–515.
216. Hijikata, M., Ohta, Y., Mishiro, S., Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt –88) correlated with the response of hepatitis C patients to interferon. Intervirology 43 (2000), 124–127.
217. Matsuyama, N., Mishiro, S., Sugimoto, M., Furuichi, Y., Hashimoto, M., Hijikata, M., Ohta, Y., The dinucleotide microsatellite polymorphism of the IFNAR1 gene promoter correlates with responsiveness of hepatitis C patients to interferon. Hepatol. Res. 25 (2003), 221–225.
218. Pang, P.S., Planet, P.J., Glenn, J.S., The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy. PLoS One, 4, 2009, e6579.
219. Brunetto, M.R., Moriconi, F., Bonino, F., Lau, G.K., Farci, P., Yurdaydin, C., Piratvisuth, T., Luo, K., Wang, Y., Hadziyannis, S., Wolf, E., McCloud, P., Batria, R., Marcellin, P., Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 49 (2009), 1141–1150.
220. Caruntu, F.A., Streinu-Cercel, A., Gheorghe, L.S., Grigorescu, M., Sporea, I., Stanciu, C., Andronescu, D., Voinea, F., Diculescu, M., Oproiu, A., Voiosu, R., Efficacy and safety of peginterferon alpha-2a (40KD) in HBeAg-positive chronic hepatitis B patients. J. Gastrointestin. Liver Dis. 18 (2009), 425–431.
221. Keating, G.M., Peginterferon-alpha-2a (40 kD): a review of its use in chronic hepatitis B. Drugs 69 (2009), 2633–2660.
222. Alric, L., Bonnet, D., Laurent, G., Kamar, N., Izopet, J., Chronic hepatitis E virus infection: successful virologic response to pegylated interferon-alpha therapy. Ann. Intern. Med. 153 (2010), 135–136.
223. Kamar, N., Abravanel, F., Garrouste, C., Cardeau-Desangles, I., Mansuy, J.M., Weclawiak, H., Izopet, J., Rostaing, L., Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient. Nephrol. Dial. Transplant. 25 (2010), 2792–2795.
224. van de Garde, M.D.B., Pas, S.D., van Oord, G.W., Gama, L., Choi, Y., de Man, R.A., Boonstra, A., Vanwolleghem, T., Interferon-alpha treatment rapidly clears Hepatitis E virus infection in humanized mice. Sci. Rep., 7, 2017, 8267.
225. Haagmans, B.L., Kuiken, T., Martina, B.E., Fouchier, R.A., Rimmelzwaan, G.F., van Amerongen, G., van Riel, D., de Jong, T., Itamura, S., Chan, K.H., Tashiro, M., Osterhaus, A.D., Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat. Med. 10 (2004), 290–293.
226. Blatt, L.M., Davis, J.M., Klein, S.B., Taylor, M.W., The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J. Interferon Cytokine Res. 16 (1996), 489–499.
227. Klein, S.B., Blatt, L.M., Taylor, M.W., Cell surface binding characteristics correlate with consensus type I interferon enhanced activity. J. Interferon Cytokine Res. 16 (1996), 1–6.
228. Melian, E.B., Plosker, G.L., IFN alfacon-1: a review of pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C. Drugs 61 (2001), 1661–1691.
229. Loutfy, M.R., Blatt, L.M., Siminovitch, K.A., Ward, S., Wolff, B., Lho, H., Pham, D.H., Deif, H., LaMere, E.A., Chang, M., Kain, K.C., Farcas, G.A., Ferguson, P., Latchford, M., Levy, G., Dennis, J.W., Lai, E.K., Fish, E.N., Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 290 (2003), 3222–3228.
230. Kumaki, Y., Day, C.W., Wandersee, M.K., Schow, B.P., Madsen, J.S., Grant, D., Roth, J.P., Smee, D.F., Blatt, L.M., Barnard, D.L., Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells. Biochem. Biophys. Res. Commun. 371 (2008), 110–113.
231. Kumaki, Y., Day, C.W., Bailey, K.W., Wandersee, M.K., Wong, M.H., Madsen, J.R., Madsen, J.S., Nelson, N.M., Hoopes, J.D., Woolcott, J.D., McLean, T.Z., Blatt, L.M., Salazar, A.M., Smee, D.F., Barnard, D.L., Induction of interferon-gamma-inducible protein 10 by SARS-CoV infection, interferon alfacon 1 and interferon inducer in human bronchial epithelial Calu-3 cells and BALB/c mice. Antivir. Agents Chemother. 20 (2010), 169–177.
232. Smith, L.M., Hensley, L.E., Geisbert, T.W., Johnson, J., Stossel, A., Honko, A., Yen, J.Y., Geisbert, J., Paragas, J., Fritz, E., Olinger, G., Young, H.A., Rubins, K.H., Karp, C.L., Interferon Β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J. Infect. Dis. 208 (2013), 310–318.
233. Jahrling, P.B., Geisbert, T.W., Geisbert, J.B., Swearengen, J.R., Bray, M., Jaax, N.K., Huggins, J.W., LeDuc, J.W., Peters, C.J., Evaluation of immune globulin and recombinant interferon-Α2b for treatment of experimental Ebola virus infections. J. Infect. Dis. 179 (1999), S224–234.
234. Qiu, X., Wong, G., Fernando, L., Aubet, J., Bello, A., Strong, J., Alimonti, J.B., Kobinger, G.P., mABs and Ad-vectored IFN-Α therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms. Sci. Transl. Med., 5, 2013, 207ra 143.
235. McCarthy, S.D.S., Majchrzak-Kita, B., Racine, T., Kozlowski, H.N., Baker, D.P., Hoenen, T., Kobinger, G.P., Fish, E.N., Branch, D.R., A rapid screening assay identifies monotherapy with interferon-Β and combination therapies with nucleoside analogs as effective inhibitors of Ebola virus. PLoS Negl. Trop. Dis., 10, 2016, e0004364.
236. Konde, M.K., Baker, D.P., Traore, F.A., Sow, M.S., Camara, A., Barry, A.A., Mara, D., Barry, A., Cone, M., Kaba, I., Richard, A.A., Beavogui, A.H., Günther, S., European Mobile Laboratory Consortium, Pintilie, M., Fish, E.N., Interferon Β-1a for the treatment of Ebola virus disease: a historically controlled, single-arm proof-of-concept trial. PLoS One, 12, 2017, e0169255.
237. Wang, B.X.Wang B.X., Wei, L., Kotra, L.P., Brown, E.G., Fish, E.N., A conserved residue, tyrosine (Y) 84, in H5N1 influenza A virus NS1 regulates IFN signaling responses to enhance viral infection. Viruses, 9, 2017, E107.
238. Slonchak, A., Clarke, B., Mackenzie, J., Amarilla, A.A., Setoh, Y.X., Khromykh, A.A., West Nile virus infection and interferon alpha treatment alter the spectrum and the levels of coding and noncoding host RNAs secreted in extracellular vesicles. BMC Genomics, 20, 2019, 474.
239. Konishi, H., Okamoto, K., Ohmori, Y., Yoshino, H., Ohmori, H., Ashihara, M., Hirata, Y., Ohta, A., Sakamoto, H., Hada, N., Katsume, A., Kohara, M., Morikawa, K., Tsukuda, T., Shimma, N., Foster, G.R., Alazawi, W., Aoki, Y., Arisawa, M., Sudoh, M., An orally available, small-molecule interferon inhibits viral replication. Sci. Rep., 2, 2012, 259.
240. Furutani, Y., Toguchi, M., Shiozaki-Sato, Y., Qin, X.Y., Ebisui, E., Higuchi, S., Sudoh, M., Suzuki, H., Takahashi, N., Watashi, K., Wakita, T., Kakeya, H., Kojima, S., An interferon-like small chemical compound CDM-3008 suppresses hepatitis B virus through induction of interferon-stimulated genes. PLoS One, 14, 2019, e0216139.
241. Sun, J., Ennis, J., Turner, J.D., Chu, J.J., Single dose of an adenovirus vectored mouse interferon-Α protects mice from lethal EV71 challenge. Antiviral Res. 134 (2016), 207–215.
242. Richardson, J.S., Wong, G., Pillet, S., Schindle, S., Ennis, J., Turner, J., Strong, J.E., Kobinger, G.P., Evaluation of different strategies for post-exposure treatment of Ebola virus infection in rodents. J. Bioterror. Biodef., S1, 2011, 007.
243. Dagley, A., Ennis, J., Turner, J.D., Rood, K.A., Van Wettere, A.J., Gowen, B.B., Julander, J.G., Protection against Chikungunya virus induced arthralgia following prophylactic treatment with adenovirus vectored interferon (mDEF201). Antiviral Res. 108 (2014), 1–9.
244. Gowen, B.B., Ennis, J., Bailey, K.W., Vest, Z., Scharton, D., Sefing, E.J., Turner, J.D., Single-dose intranasal treatment with DEF201 (adenovirus vectored consensus interferon) prevents lethal disease due to Rift Valley fever virus challenge. Viruses 6 (2014), 1410–1423.
245. Baek, Y.H., Song, M.S., Lee, E.-Y., Kim, Y.I., Kim, E.H., Park, S.J., Park, K.J., Kwon, H.I., Pascua, P.N., Lim, G.J., Kim, S., Yoon, S.W., Kim, M.H., Webby, R.J., Choi, Y.K., Profiling and characterization of influenza N1 strains potentially resistant to multiple neuraminidase inhibitors. J. Virol. 89 (2015), 287–299.